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Background: Cordyceps militaris is a well-known fungus with immunomodulatory 
activity. It is generally used in traditional Chinese medicine to treat hemoptysis, 
bronchial or lung inflammation, and urogenital disorders. The purpose of our study 
was to evaluate the effect of cultivated C. militaris on airway inflammation in a 
mouse asthma model.
Methods: BALB/c mice were sensitized with intraperitoneal ovalbumin (OVA) on 
Days 0 and 14, and were then given intranasal OVA on Day 14 and Days 25−27. 
Randomized treatment groups of sensitized mice were administered C. militaris, 
prednisolone, montelukast, or placebo by gavage from Days 15−27. Airway hyper-
reactivity to aerosolized methacholine was determined. Bronchoalveolar lavage 
fluid and serum were analyzed to assess airway inflammation.
Results: OVA-sensitized mice developed a significant airway inflammatory response 
that was inhibited by prednisolone and montelukast, whilst C. militaris reduced 
airway inflammation less effectively. Airway hyperresponsiveness to methacholine 
was observed in OVA-sensitized mice and was reversed by both prednisolone and 
montelukast. C. militaris initially reversed airway hyperreactivity, but this effect 
disappeared at higher methacholine doses.
Conclusion: C. militaris can modulate airway inflammation in asthma, but it is less 
effective than prednisolone or montelukast. These results demonstrate that C. militaris 
is unable to adequately block the potent mediators of asthmatic airway inflammation.
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1. Introduction
Asthma is a complex disease that affects millions of 
people and its incidence has increased substantially 
over the last two decades. Asthma is initially char-
acterized by airway hyperresponsiveness (AHR) 
to a variety of specific or nonspecific provocative 
stimuli,1 by mucus hypersecretion, pulmonary 
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eosinophilia, airway edema, and elevated serum 
immunoglobulin E (IgE) levels.2 Persistent allergen 
stimulation induces chronic airway inflammatory 
changes, which are usually accompanied by airway 
remodeling.3,4 Chronic asthma is thus difficult to 
control using inhaled β2 agonists alone.5−7 These air-
way changes, however, can be found in both newly 
diagnosed and chronic asthma patients.4
Cysteinyl leukotrienes (CysLTs) are now recog-
nized as major mediators involved in the patho-
genic changes of airway inflammation. They exert 
most of their bronchoconstrictive and proinflam-
matory effects through activation of a putative, 
7-transmembrane domain, G-protein-coupled CysLT1 
receptor.8 CysLT receptors are distributed diffusely 
in human lung smooth muscle cells, interstitial mac-
rophages, precursor granulocytes, mast cells, ba-
sophils, eosinophils, and monocytes. Thus, CysLTs 
can augment inflammatory cell recruitment into 
the asthmatic airway through autocrine and para-
crine mechanisms.8,9 Corticosteroids exert well 
documented, anti-inflammatory effects by which 
they decrease the influx of eosinophils and other 
inflammatory cells into the blood, airways, and in-
terstitial lung tissue.10,11 The administration of cor-
ticosteroids during or after an allergen challenge 
blocks the airway inflammatory response.10,12,13 
To date, corticosteroids, the leukotriene receptor 
antagonist, montelukast, and β2 agonists are there-
fore the major medicines used in clinical practice 
for the treatment of asthma. Nevertheless, no sat-
isfactory therapy is available for long-term asthma 
control.
Cordyceps militaris (also called north winter 
worm summer grass) is a major parasitic fungus 
that grows on the larvae of Lepidoptera.14−16 It 
is one of the well known fungi used in traditional 
Chinese medicine for the treatment of asthma, and 
bronchial and lung inflammation.17 It has multiple 
therapeutic functions including anti-tumor, anti-
metastatic, immunomodulatory, and antioxidant 
effects.18 Owing to the rarity of wild C. sinensis 
(also called winter worm summer grass), large 
amounts of cultivated C. militaris are manufac-
tured by fermentation technology. Based on the 
similar compositions and bioactive effects of C. 
militaris and C. sinensis,14,18−21 C. sinensis is grad-
ually being replaced by C. militaris in the mar-
ketplace. However, the pharmacological activity 
and the effect of C. militaris on asthma remain 
unclear.
The purpose of the present study was to com-
pare the effects of C. militaris with the cortico-
steroid, prednisolone, and the leukotriene receptor 
antagonist, montelukast, on systemic IgE produc-
tion, airway inflammation and pulmonary function 
in a mouse asthma model. In the present in vivo 
study, the therapeutic agents were all administered 
by gavage, which is rarely used in such studies.11 
This method of administration may more closely ap-
proximate the physiological conditions encountered 
in daily practice.
2. Methods
2.1.  Allergen immunization/challenge 
protocol
All animal procedures were approved by the Ethic 
and Animal Care Committee of Chung-Shan Medical 
University. Female BALB/c mice, 6−8 weeks of age, 
were obtained from the National Laboratory Animal 
Center in Taiwan (six mice/group). The mice were 
maintained on ovalbumin (OVA)-free diets.
The mice were immunized by intraperitoneal 
(i.p.) injections of 100 μg OVA (0.2 mL of 0.5 mg/mL) 
(grade V; Sigma Chem. Co., St Louis, USA) com-
plexed with alum (Sigma Chem. Co.) on Days 0 and 
14.22,23 In the age and sex-matched control group, 
un sensitized mice received an i.p. injection of 0.2 mL 
saline complexed with alum. Intranasal (i.n.) OVA 
challenge was first given at a dose of 100 μg (0.05 mL 
of 2 mg/mL) on Day 14. The i.n. OVA challenges 
were then repeated on Days 25, 26, and 27 using a 
dose of 50 μg (0.05 mL of 1 mg/mL). In the control 
group, unsensitized mice received 50 μL of normal 
saline i.n. on Day 14 and Days 25, 26, and 27. 
Normal saline was used as a negative control.
2.2.  Preparation and extraction of the 
fruiting bodies of C. militaris
The dry fruiting bodies of C. militaris were har-
vested from the larvae of Bombyx mori L. by a fer-
mentation process.20 One hundred grams of 
C. militaris fruiting body powder (obtained from 
the Microbiology and Immunology Department of 
Chung-Shan Medical University) were added to 1 L 
deionized water at 100ºC for 30 minutes.24 The 
solid residue was dissolved and filtered using 
Waterman No. 3 filter paper. A concentration of 
100 mg/mL crude extract was then stored at 4ºC 
until use.
2.3.  Therapeutic intervention with a 
corticosteroid, a leukotriene receptor 
antagonist, and C. militaris
On Days 15−27, randomized treatment groups were 
fed different agents by gavage. An OVA-treated group 
was fed with the leukotriene receptor antagonist, 
montelukast (0.8 mg/kg/day, dissolved in apple juice; 
Merck and Co., Inc., Northumberland, UK).9,12,25 
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Another OVA-treated group was fed with cultivated 
C. militaris fluid (4 g/kg/day). This dosage was pre-
viously reported to inhibit airway inflammation.17,26 
The positive control group was fed with prednisolone 
sodium phosphate solution (3 mg/kg/day; Central 
Labora tories, Inc., Hsinchu County, Taiwan).11 Another 
group of unsensitized mice and a group of OVA-
treated mice were fed apple juice as a placebo.
2.4.  Determination of airway 
responsiveness using noninvasive 
pulmonary function testing
On Day 28, 24 hours after the last i.n. challenge 
with either normal saline or OVA, pulmonary me-
chanics were determined noninvasively using whole-
body plethysmography (Model PLY 3211; Buxco 
electronics, Inc., Sharon, CT, USA).27 AHR to aero-
solized methacholine was determined in conscious, 
freely moving, spontaneously breathing mice. Dif-
ferent concentrations of aerosolized methacholine 
(0, 5, 10, 20 mg/mL) were used. The degree of bron-
choconstriction was expressed as the enhanced 
pause (Penh), a calculated dimensionless value that 
correlates with measurements of airway resistance, 
impedance, and intrapleural pressure.
2.5.  Immunoassay for specific serum 
antibody levels
The mice were sacrificed after plethysmography 
and each mouse was exsanguinated by cardiac 
puncture. Blood was centrifuged at 6000 rpm for 5 
minutes at 4ºC to separate the serum. An indirect 
enzyme-linked immunosorbent assay (ELISA) (Alpha 
Diagnostics Intl., Inc., San Antonio, TX, USA) was 
used to determine serum IgE antibody titers. Opti-
cal density (OD) readings of the samples were ob-
tained by measuring the absorbance at 450 nm 
using an ELISA reader. The antibody titers of the sam-
ples were related to pooled standards generated 
in the laboratory and expressed as ng/mL.
2.6.  Acquisition of bronchoalveolar lavage 
fluid (BALF) and quantitation of 
BALF cells
Bronchoalveolar lavage (BAL) was performed after 
exsanguination. The right lung was separated 
by ligation at the right mainstem bronchus and BAL 
of the left lung was performed. The BALF was cen-
trifuged at 1000 g for 5 minutes at 4ºC. The super-
natant was then removed and frozen at −80ºC for 
subsequent testing. The pellet was resuspended and 
10 μL of the resuspended BALF was stained with 
0.06% methylene blue to determine the total leu-
kocyte counts using a hemocytometer. Then, 200 μL 
of diluted BALF cell suspension was aliquoted into 
the cytocentrifuge’s single chamber cytospin device 
(Rotofix 32; Andreas Hettich GmbH & Co. KG., 
Tuttlingen, Germany) and the samples were centri-
fuged at 500 rpm for 4 minutes at room tempera-
ture. Slides were stained with hematoxylin and eosin 
for eosinophil counts. Differential counts were per-
formed in a blinded fashion by counting at least 
300 cells under a light microscope.
2.7. Lung histology
After BAL, the trachea and right lung were fixed in 
formalin at room temperature for about 15 hours. 
The right lung tissue was then embedded in paraf-
fin and cut into 5 μm sections. The lung sections 
were stained with hematoxylin and eosin to deter-
mine the degree of airway inflammatory cell infil-
tration and smooth muscle thickness. Between five 
and eight fields on each slide were randomly 
examined to evaluate morphometric variation.
2.8. Statistical analyses
The data are reported as the mean ± SEMs of the 
combined experiments. The results of the different 
groups were compared using analysis of variance 
(ANOVA) with the protected least significant dif-
ference method. Differences between groups were 
considered statistically significant when p values 
were < 0.05.
3. Results
3.1. Serum IgE production
Serum IgE levels were significantly elevated in 
the OVA sensitized/challenged group (1833.52 ± 
402.03 ng/mL) compared with the saline-treated 
control group (121.61 ± 10.48 ng/mL, p < 0.001; Figure 
1). In OVA-treated mice given prednisolone (574.03 ± 
120.71 ng/mL, p = 0.001 vs. sensitized group) or 
montelukast (284.46 ± 45.41 ng/mL, p < 0.001 vs. 
sensitized group) during repeated OVA challenges, 
serum IgE release was significantly decreased in 
both groups. In OVA-treated mice given C. milita-
ris (1591.35 ± 350.68 ng/mL, p = 0.49 vs. sensitized 
group), the serum IgE level was reduced by only 
13.2%, which was not significantly different from 
the sensitized control group.
3.2. Airway inflammatory cell infiltration
Airway inflammatory cells markedly infiltrated 
into the BALF in the OVA-sensitized/challenged 
group (11.83 ± 2.20 × 105/mL) compared to the 
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saline-treated control group (1.58 ± 0.55 × 105/mL, 
p < 0.001; Figure 2). Both prednisolone (3.83 ± 0.60 × 
105/mL, p < 0.001 vs. sensitized group) and monte-
lukast (4.33 ± 0.85 × 105/mL, p = 0.001 vs. sensitized 
group) given to OVA-treated mice during repeated 
OVA challenges significantly reduced the infiltra-
tion of airway inflammatory cells into the BALF. 
In contrast, the effect of C. militaris on the reduc-
tion of BALF inflammatory cells (8.50 ± 1.71 × 105/mL) 
was not significantly different from that seen in 
the control OVA-treated group (p = 0.094). Airway 
inflammatory cells in BALF were only reduced by 
28% by C. militaris.
3.3.  Bronchoalveolar lavage fluid 
eosinophilia
The percentage of BALF eosinophils was signifi-
cantly greater in the OVA-treated group (50.83% ± 
4.35%) than in the normal saline-treated group 
(0.89% ± 0.17%, p < 0.001; Figure 3). Both prednisolone 
(22.94% ± 8.90%, p = 0.002 vs. sensitized group) and 
montelukast (16.28% ± 6.52%, p < 0.001 vs. sensitized 
group) significantly reduced eosinophil influx into 
BALF in OVA-treated mice. The administration of 
C. militaris (44.0% ± 4.89%, p = 0.41 vs. sensitized 
group) during repeated OVA challenges caused no 
significant reduction in the percentage of eosinophils 
in the BALF.
3.4. Noninvasive in vivo plethysmography
Airway reactivity to aerosolized methacholine was 
evaluated using noninvasive plethysmography on 
Day 28, 24 hours after the last intranasal challenge 
with OVA or saline (Figure 4). Penh (% of air) was 
significantly increased in the OVA-treated group 
compared with saline controls after challenge with 
methacholine 5 mg/mL (p < 0.001, OVA vs. saline), 
10 mg/mL (p = 0.003, OVA vs. saline), and 20 mg/mL 
(p = 0.004, OVA vs. saline). Penh was significantly re-
duced in the prednisolone/OVA group after metha-
choline challenge at 5 mg/mL (p = 0.004, OVA vs. 
prednisolone/OVA), 10 mg/mL (p = 0.009, OVA vs. 
prednisolone/OVA), and 20 mg/mL (p = 0.014, OVA 
vs. prednisolone/OVA). Similar results were ob-
served in the montelukast/OVA group; Penh was 
significantly reduced after methacholine challenge 
at 5 mg/mL (p = 0.003, OVA vs. montelukast/OVA), 
10 mg/mL (p = 0.02, OVA vs. montelukast/OVA), and 
20 mg/mL (p = 0.012, OVA vs. montelukast/OVA). In 
the C. militaris/OVA group, Penh was significantly 
reduced after methacholine challenge at 5 mg/mL 
(p = 0.025, OVA vs. C. militaris/OVA) and 10 mg/mL 
(p = 0.031, OVA vs. C. militaris/OVA). However, after 
higher doses (20 mg/mL) of methacholine, C. militaris 
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Figure 1 Effect of treatment with C. militaris, a CysLTs 
receptor antagonist and a corticosteroid on serum IgE 
levels in OVA-treated mice. Serum IgE levels were deter-
mined in the saline-treated group and the OVA-sensitized/
challenged group with and without treatment with pred-
nisolone (3 mg/kg), montelukast (0.8 mg/kg) or C. mili-
taris (CM, 4 g/kg). The results are expressed as means ± 
SEM. n = 6 in each group. *p < 0.05, compared with the 
OVA-treated group (ANOVA).
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Figure 2 Effect of treatment with C. militaris, a CysLTs 
receptor antagonist and a corticosteroid on inflamma-
tory cell infiltration in the BALF of OVA-treated mice. 
BALF was obtained from the saline-treated group and 
the OVA-sensitized/challenged group with and without 
treatment with prednisolone (3 mg/kg), montelukast 
(0.8 mg/kg) or C. militaris (CM, 4 g/kg). The total cell 
counts (×105) per mL of BALF were determined based on 
morphometric evaluation of cytospin preparations. C. 
militaris treatment had no significant effect on decreas-
ing total BALF cell counts. The results are expressed as 
means ± SEM. n = 6 in each group. *p < 0.05, compared 
with the OVA-treated group (ANOVA).
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had no significant effect on the airway responses 
to methacholine in the OVA-sensitized/challenged 
group (Figure 4).
3.5.  Airway inflammatory changes 
demonstrated by histology
Cross-sections of the right lung obtained from OVA-
treated and saline-treated control groups were 
examined using light microscopy to assess inflam-
matory cell and smooth muscle cell hyperplasia 
in the airways (Figure 5). No evidence of inflam-
matory cell infiltration or airway smooth muscle 
thickening was observed in controls. In contrast, 
morphologic evidence of widespread inflammatory 
cell infiltration and airway smooth muscle thicken-
ing was seen in the OVA-treated group (Figure 
5B). In the airways of OVA-sensitized/challenged 
mice, inflammatory cell infiltration was effectively 
blocked by both prednisolone and montelukast 
treatment (Figures 5C and 5D). Furthermore, both 
prednisolone and montelukast reversed the thick-
ened airway smooth muscle in the OVA sensitized/
challenged group (Figures 5C and 5D) shown by 
hematoxylin and eosin staining. However, C. mili-
taris only partially blocked the development of 
airway inflammatory cell infiltration and smooth 
muscle layer thickening in the OVA-treated group 
(Figure 5E).
4. Discussion
Cultivated C. militaris is now widely used in Asia 
as a substitute for wild C. sinensis because of its 
similar bioactive effects and most importantly, the 
facilities for its mass production in a laboratory. 
However, the use of different species of Cordyceps 
with different proportions of components results 
in variable effects of this traditional Chinese med-
icine when used for asthma treatment.16,17,26,28 
An allergen-induced, mouse airway inflammatory 
model was used to study the effects of C. militaris 
on pulmonary inflammation. C. militaris was com-
pared with the potent inflammatory inhibitor, pred-
nisolone, and the leukotriene receptor antagonist, 
montelukast, as CysLTs are now recognized to be the 
most potent mediators involved in promoting air-
way inflammation, remodeling and hyperreactivity 
to methacholine exposure.
Mice can develop IgE-mediated allergic re-
sponses. In addition to elevated serum IgE levels in 
OVA-sensitized/challenged mice, AHR to metha-
choline and a late-phase influx of eosinophils were 
also noted in this mouse asthma model. Eosinophils 
modulate the function of mesenchymal cells, in-
cluding fibroblasts and myofibroblasts, thus chang-
ing the composition of the airway wall matrix.29 
The development of allergic airway disease with 
consequent structural changes driven by IgE or 
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Figure 3 Effect of treatment with C. militaris, a CysLTs 
receptor antagonist and a corticosteroid on the percent-
age of eosinophil infiltration in the BALF of OVA-treated 
mice. The percentages of eosinophil (%) infiltration in 
the BALF were determined based on morphometric eval-
uation of cytospin preparations. C. militaris treatment 
had no significant effect on reducing the percentages of 
eosinophil (%) infiltration. The results are expressed as 
means ± SEM. n = 6 in each group. *p < 0.05, compared 
with the OVA-treated group (ANOVA).
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Figure 4 Effect of treatment with C. militaris, a CysLTs 
receptor antagonist and a corticosteroid on the pulmo-
nary function response to aerosolized methacholine. 
The degree of bronchoconstriction (expressed as Penh 
[% of air]) to aerosolized methacholine (0, 5, 10 and 20 mg/
mL) was determined on Day 28 in saline-treated mice and 
OVA-treated mice in the absence or presence of pred-
nisolone, montelukast or C. militaris treatment. The results 
are expressed as means ± SEM. n = 6 in each group. *p < 
0.05, compared with all other groups; **p < 0.05, com-
pared with the OVA-treated group (ANOVA).
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other Th2 cyto kines can then follow. Levels of 
serum IgE, AHR and airway inflammatory cells, in-
cluding eosinophils, can be suppressed by the use 
of corticosteroids and montelukast during allergen 
challenge. These results suggest that CysLTs are 
the major mediators leading the process of airway 
inflammation.
Here, C. militaris treatment was less effective 
than corticosteroids or montelukast in inhibiting 
serum IgE levels, eosinophil infiltration and AHR. 
Unlike the potent anti-inflammatory effects that 
corticosteroids exert on most cells, Cordyceps 
mainly acts by inhibiting phagocytosis and chemo-
taxis of neutrophils and natural killer cells.26,28 
However, the characteristic of allergic airway in-
flammation is eosinophil recruitment. Eosinophil is 
not the main cell upon which Cordyceps can act. 
Cordyceps is also unable to inhibit the production 
of leukotrienes,26 which are potent mediators of 
bronchoconstriction and airway inflammation.30,31 
This may explain the limited reversal of airway hy-
perresponsiveness in sensitized mice and the need 
A B
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100 μm 100 μm
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100 μm
100 μm
Figure 5 Effect of treatment with C. militaris, a CysLT receptor antagonist and a corticosteroid on allergen-induced 
airway inflammation. Lung tissue was obtained on Day 28 from saline controls (A) and OVA-treated mice in the 
absence (B) or presence of prednisolone (C), montelukast (D) or C. militaris (E); the tissues were stained with hema-
toxylin and eosin. (A) There is a scarcity of inflammatory cells around the airway in saline-treated controls; no airway 
smooth muscle thickening is observed. (B) Large numbers of inflammatory cells (arrow) are seen near the peribron-
chial tissue of OVA-treated mice; thickening of the airway smooth muscle layer (arrowhead) is also noted in this 
group. (C) Massive inflammatory cell infiltration and hyperplasia of the airway smooth muscle layer were markedly 
reduced when prednisolone was given during repeated OVA challenges. (D) Inflammatory cell infiltration and hyper-
plasia of the airway smooth muscle layer were also markedly reduced by montelukast during repeated OVA chal-
lenges. (E) Inflammatory cell infiltration (arrow) and hyperplasia of the airway smooth muscle layer (arrowhead) 
were partially reversed when C. militaris was given during repeated OVA challenges.
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for higher C. militaris doses to suppress the hyper-
reactive airway.17 Recent studies have suggested 
that the therapeutic activity of Cordyceps in asthma 
may be related to its content of immunomodulatory 
agents. These immunomodulatory agents may en-
hance a Th1 cell-mediated immune response, so re-
ducing the Th2 cell-mediated immune response.16,17 
The prominent cytokine associated with the Th1 cell 
immune response is interferon-γ, which enhances 
IgG2a production and inhibits IgG1 and IgE produc-
tion in B lymphocytes. Nevertheless, limited en-
hancement of IgG2a but no significant inhibition of 
IgG1 and IgE were noted in the present study (data 
not shown). Different species of Cordyceps and 
different culture conditions may contribute to such 
discrepancies. In previous studies, only specific 
fractions of Cordyceps resulting from the extrac-
tion process have been examined for immunomod-
ulatory effects.16,28,32,33 In contrast, our study used 
whole C. militaris extract, as do most people who 
use it as a health food product. This may be re-
sponsible for the lower efficacy of C. militaris in 
reducing airway inflammation.
In summary, our results indicate that a crude 
extract of C. militaris was unable to adequately 
inhibit asthmatic airway inflammation. C. militaris 
was not as effective as prednisolone or monte-
lukast in reversing AHR; neither did C. militaris 
block the potent bronchoconstriction mediators−
leukotrienes. C. militaris is therefore only suitable 
for use as an auxiliary agent in asthma control. The 
isolation of pure bioactive factors from C. milita-
ris is required in order to help determine the 
mechanisms of C. militaris action on the asthmatic 
airway.
Acknowledgments
The study was supported by a research grant from 
the Chung Shan Medical University Hospital (CSH-
97-B-03), Taichung, Taiwan.
References
1. Chetta A, Foresi A, Del Donno M, et al. Bronchial respon-
siveness to distilled water and methacholine and its rela-
tionship to inflammation and remodeling of the airways in 
asthma. Am J Respir Crit Care Med 1996;153:910−7.
2. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: cen-
tral mediator of allergic asthma. Science 1998;282:
2258−61.
3. Jeffery PK. Remodeling in asthma and chronic obstructive 
lung disease. Am J Respir Crit Care Med 2001;164:S28−38.
4. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, 
Olivieri D. Airway remodeling is a distinctive feature of 
asthma and is related to severity of disease. Chest 1997;111:
852−7.
5. Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting 
beta2-agonists for chronic asthma in adults and children 
where background therapy contains varied or no inhaled cor-
ticosteroid. Cochrane Database Syst Rev 2007:CD001385.
6. Kelly HW. Risk versus benefit considerations for the beta 2-
agonists. Pharmacotherapy 2006;26:164S−74S.
7. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assess-
ment of inhaled long-acting beta2-agonists in the manage-
ment of obstructive pulmonary disease. Drug Saf 2004;27:
689−715.
8. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the 
cysteinyl leukotriene 1 receptor in normal human lung and 
peripheral blood leukocytes. Am J Respir Crit Care Med 
2001;163:226−33.
9. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, 
a leukotriene receptor antagonist, reduces the concentra-
tion of leukotrienes in the respiratory tract of children 
with persistent asthma. J Allergy Clin Immunol 1999;104:
1162−7.
10. Eum SY, Maghni K, Hamid Q, et al. Inhibition of allergic 
airways inflammation and airway hyperresponsiveness in 
mice by dexamethasone: role of eosinophils, IL-5, eotaxin, 
and IL-13. J Allergy Clin Immunol 2003;111:1049−61.
11. Kumar RK, Herbert C, Thomas PS, et al. Inhibition of inflam-
mation and remodeling by roflumilast and dexamethasone 
in murine chronic asthma. J Pharmacol Exp Ther 2003;307:
349−55.
12. Henderson WR, Jr., Chiang GK, Tien YT, Chi EY. Reversal of 
allergen-induced airway remodeling by CysLT1 receptor 
blockade. Am J Respir Crit Care Med 2006;173:718−28.
13. Trifilieff A, El-Hashim A, Bertrand C. Time course of inflam-
matory and remodeling events in a murine model of asthma: 
effect of steroid treatment. Am J Physiol Lung Cell Mol 
Physiol 2000;279:L1120−8.
14. Meng QF, Lin XY, Lin W, Feng Y, Teng LR. Comparison of 
amino acid contents between cultivated Cordyceps milita-
ris and wild Cordyceps sinensis. Amino Acids and Biotic 
Resources 2005;27:33−4.
15. Duh PD. Rebuttal on comparison of protective effects 
between cultured Cordyceps militaris and natural Cordyceps 
sinensis against oxidative damage. J Agric Food Chem 2007;
55:7215−6.
16. Kuo YC, Tsai WJ, Wang JY, Chang SC, Lin CY, Shiao MS. 
Regulation of bronchoalveolar lavage fluids cell function 
by the immunomodulatory agents from Cordyceps sinensis. 
Life Sci 2001;68:1067−82.
17. Lin XX, Xie QM, Shen WH, Chen Y. Effects of fermented 
Cordyceps powder on pulmonary function in sensitized guinea 
pigs and airway inflammation in sensitized rats. Zhongguo 
Zhong Yao Za Zhi 2001;26:622−5.
18. Ng TB, Wang HX. Pharmacological actions of Cordyceps, a 
prized folk medicine. J Pharm Pharmacol 2005;57:
1509−19.
19. Gu YX, Song YW, Fan LQ, Yuan QS. Antioxidant activity 
of natural and cultured Cordyceps sp. Zhongguo Zhong Yao 
Za Zhi 2007;32:1028−31.
20. Kim HO, Yun JW. A comparative study on the production of 
exopolysaccharides between two entomopathogenic fungi, 
Cordyceps militaris and Cordyceps sinensis in submerged 
mycelial cultures. J Appl Microbiol 2005;99:728−38.
21. Yu HM, Wang BS, Huang SC, Duh PD. Comparison of protec-
tive effects between cultured Cordyceps militaris and nat-
ural Cordyceps sinensis against oxidative damage. J Agric 
Food Chem 2006;54:3132−8.
22. Henderson WR, Jr., Tang LO, Chu SJ, Tsao SM, Chiang GK, 
Jones F, et al. A role for cysteinyl leukotrienes in airway 
remodeling in a mouse asthma model. Am J Respir Crit 
Care Med 2002;165:108−16.
178 C.H. Hsu et al
23. Henderson WR, Jr., Lewis DB, Albert RK, et al. The impor-
tance of leukotrienes in airway inflammation in a mouse 
model of asthma. J Exp Med 1996;184:1483−94.
24. Ikumoto T, Sasaki S, Namba H, Toyama R, Moritoki H, Mouri 
T. Physiologically active compounds in the extracts from 
tochukaso and cultured mycelia of Cordyceps and Isaria. 
Yakugaku Zasshi 1991;111:504−9.
25. Wong WS, Zhu H, Liao W. Cysteinyl leukotriene receptor 
antagonist MK-571 alters bronchoalveolar lavage fluid 
proteome in a mouse asthma model. Eur J Pharmacol 
2007.
26. Lin YG, Chen JL, Wu YH, Chen YP, Yang XH. Influence of 
Cordyceps on PMN activation of human race. Shanghai J 
Trad Chinese Med 2003;37:49−51.
27. Hamelmann E, Schwarze J, Takeda K, et al. Noninvasive 
measurement of airway responsiveness in allergic mice 
using barometric plethysmography. Am J Respir Crit Care 
Med 1997;156:766−75.
28. Kuo YC, Tsai WJ, Shiao MS, Chen CF, Lin CY. Cordyceps sinen-
sis as an immunomodulatory agent. Am J Chin Med 1996;
24:111−25.
29. Pascual RM, Peters SP. Airway remodeling contributes to 
the progressive loss of lung function in asthma: an overview. 
J Allergy Clin Immunol 2005;116:477−86; quiz 87.
30. Hines RN, McCarver DG. Pharmacogenomics and the future 
of drug therapy. Pediatr Clin North Am 2006;53:591−619.
31. Hawkins GA, Weiss ST, Bleecker ER. Asthma pharmacoge-
nomics. Immunol Allergy Clin North Am 2005;25:723−42.
32. Huang LF, Chen BM, Guo FQ, Liang YZ. Determination of ade-
nosine and cordycepin in Cordyceps sinensis and C. militar-
ris with HPLC-ESI-MS. Zhongguo Zhong Yao Za Zhi 2004;
29:762−4.
33. Kim SW, Xu CP, Hwang HJ, Choi JW, Kim CW, Yun JW. 
Produc tion and characterization of exopolysaccharides 
from an enthomopathogenic fungus Cordyceps militaris 
NG3. Biotechnol Prog 2003;19:428−35.
